Trial Profile

A Phase 2 Pivotal Study of BCB-276, a B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Sep 2026 According to BrainChild Bio media release, the company announced the initiation of a pivotal Phase 2 clinical trial to evaluate BCB-276 for the treatment of diffuse intrinsic pontine glioma (DIPG). Site activation is complete or underway across all six selected and qualified study sites.
08 Sep 2026 According to a BrainChild Bio media release, the company announced that the company has closed a $116 million Series A financing. Proceeds from the Series A financing will be used to support the ILLUMINATE Phase 2 study to evaluate BCB-276, for the treatment of diffuse intrinsic pontine glioma (DIPG).
04 Aug 2026 Planned initiation date changed from 1 Jul 2026 to 1 Aug 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com